We are live on ! Find out more
XFOR icon

X4 Pharmaceuticals
XFOR

95 hedge funds and large institutions have $219M invested in X4 Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 46 funds opening new positions, 25 increasing their positions, 11 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

557% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 7

490% more call options, than puts

Call options by funds: $10.9M | Put options by funds: $1.85M

309% more capital invested

Capital invested by funds: $53.6M → $219M (+$165M)

127% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 11

70% more funds holding

Funds holding: 56 → 95 (+39)

0.7% more ownership

Funds ownership: 1.68% → 2.37% (+0.7%)

Holders
95
Holders Change
+39
Holders Change %
+69.64%
% of All Funds
1.49%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.03%
New
46
Increased
25
Reduced
11
Closed
7
Calls
$10.9M
Puts
$1.85M
Net Calls
+$9.06M
Net Calls Change
+$9.16M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$15M
2
SCM
Stonepine Capital Management
Oregon
+$7.89M
3
Millennium Management
Millennium Management
New York
+$7.49M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$7.33M
5
BCLSI
Bain Capital Life Sciences Investors
Massachusetts
+$6.44M

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$1.71M
2
Axa
Axa
France
-$1.66M
3
CAM
Cormorant Asset Management
Massachusetts
-$1.42M
4
JP Morgan Chase
JP Morgan Chase
New York
-$909K
5
GTC
Ghost Tree Capital
New York
-$740K
Name Holding Trade Value Shares
Change 		Change in
Stake
BCLSI
1
Bain Capital Life Sciences Investors
Massachusetts
$31M +$6.44M +125,270 +31%
NMC
2
NEA Management Company
Maryland
$29.1M +$5.57M +108,334 +28%
BlackRock
3
BlackRock
New York
$17.6M +$15M +291,723 +2,547%
Vanguard Group
4
Vanguard Group
Pennsylvania
$15.1M +$5.9M +114,761 +79%
O
5
OrbiMed
New York
$13.8M +$2.25M +43,860 +23%
Millennium Management
6
Millennium Management
New York
$10.6M +$7.49M +145,713 +405%
SCM
7
Stonepine Capital Management
Oregon
$8.93M +$7.89M +153,509 New
Adage Capital Partners
8
Adage Capital Partners
Massachusetts
$8.3M +$7.33M +142,544 New
TLP
9
Tri Locum Partners
New York
$7.95M +$379K +7,382 +6%
PHP
10
Parkman Healthcare Partners
Connecticut
$7.31M +$1.66M +32,315 +35%
PA
11
Perceptive Advisors
New York
$6.88M -$1.71M -33,333 -22%
Axa
12
Axa
France
$6.64M -$1.66M -32,383 -22%
Citadel Advisors
13
Citadel Advisors
Florida
$5.96M +$5.23M +101,858 +17,005%
AC
14
Armistice Capital
New York
$5.77M +$5.1M +99,200 New
Geode Capital Management
15
Geode Capital Management
Massachusetts
$4.56M +$2.13M +41,384 +112%
CH
16
CVI Holdings
Delaware
$4.46M +$3.94M +76,677 New
State Street
17
State Street
Massachusetts
$4.31M +$3.51M +68,298 +1,201%
KCM
18
Kingdon Capital Management
New York
$3.83M +$3.38M +65,789 New
SCM
19
Sio Capital Management
New York
$3.39M +$3M +58,300 New
Northern Trust
20
Northern Trust
Illinois
$2.04M +$1.42M +27,581 +369%
SSA
21
Schonfeld Strategic Advisors
New York
$1.91M -$91.3K -1,777 -5%
Marshall Wace
22
Marshall Wace
United Kingdom
$1.37M +$1.21M +23,478 New
Point72 Asset Management
23
Point72 Asset Management
Connecticut
$1.26M – – –
MIM
24
Monashee Investment Management
Massachusetts
$1.11M +$981K +19,093 New
EI
25
EAM Investors
California
$1.1M +$973K +18,927 New
1
2 3 4 5

XFOR Hedge Fund Activity: Q2 2023 in Review

95 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q2 2023, worth a combined $219M — up 309% from $53.6M a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new XFOR positions and 7 closed out — a net gain of 39 holders — while 25 added to existing stakes and 11 trimmed.

The largest buyer was BlackRock, adding an estimated $15M. The largest seller was Perceptive Advisors, cutting an estimated $1.71M.

  • 95 institutional investors held X4 Pharmaceuticals (XFOR) as of Q2 2023, up from 56 in Q1 2023.
  • Funds reported $219M of X4 Pharmaceuticals stock for Q2 2023, up 309% quarter-over-quarter.
  • 46 funds opened new X4 Pharmaceuticals positions in Q2 2023 and 7 closed out, a net change of +39 holders.
  • The largest X4 Pharmaceuticals buyer in Q2 2023 was BlackRock, an estimated $15M added.
  • The largest X4 Pharmaceuticals seller in Q2 2023 was Perceptive Advisors, an estimated $1.71M sold.

Based on aggregated 13F filings for Q2 2023.